Hemogenyx Pharmaceuticals Plc (LSE: HEMO), the biotechnology company developing novel therapies to transform bone marrow, or blood stem cell, transplantation for the treatment of blood diseases, confirms that the Notice of the Annual General Meeting (“AGM”) was sent to shareholders yesterday.
This document is available to view on the company website: www.hemogenyx.com
The AGM is to be held at 10:00am on Thursday 7 December 2017 at the offices of Charles Russell Speechlys LLP, 5 Fleet Place, London EC4M 7RD.
Enquiries:
| Hemogenyx Pharmaceuticals Limited | www.hemogenyx.com |
| Dr Vladislav Sandler, Chief Executive Officer & Co-Founder Dr Robin Campbell, Chairman |
Via Walbrook PR |
| Optiva Securities Ltd | Tel: +44 (0)20 3137 1902 |
| Christian Dennis | |
| Shard Capital Partners LLP | Tel: +44 (0)20 7186 9950 |
| Damon Heath, Erik Woolgar | |
| Peterhouse Corporate Finance Limited | Tel: +44 (0)20 7469 0930 |
| Lucy Williams, Duncan Vasey | |
| Walbrook PR | Tel: +44 (0)20 7933 8780 or hemogenyx@walbrookpr.com |
| Paul McManus | Mob: +44 (0)7980 541 893 |
About Hemogenyx Pharmaceuticals Plc
Hemogenyx Pharmaceuticals Plc is a publicly traded company (LSE: HEMO) headquartered in London, with its wholly owned U.S. operating subsidiary, Hemogenyx LLC, located in its state-of-the-art research facility in Brooklyn, New York. Hemogenyx is a preclinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies and treatments for blood diseases such as leukemia and lymphoma. The company’s leading technologies aim to change the way in which bone marrow/hematopoietic stem cell (BM/HSC) transplants are performed and improve their efficacy. Hemogenyx’s two distinct and complementary products include an immunotherapy product for patient conditioning-the CDX bi-specific antibody-and a cell therapy product for BM/HSC transplantation-the HuPHEC. Each of these products holds the potential to revolutionize the way BM/HSC transplants are being performed, offering solutions that mitigate the dangers and limitations associated with the current standard of care. For more information, visit www.hemogenyx.com.